Skip to main content
SpringerLink
Log in

Melanoma and Other Cutaneous Malignancies

  • Chapter
Surgery

  • 251 Accesses

Abstract

Cancers of the skin constituted nearly one-half of all cancers diagnosed in 2006, at least 1,000,000 new cases in the United States alone. In fact, the skin is by far the most common primary site for human cancer development. Although skin cancer is often thought of as causing relatively little morbidity and mortality, more than 10,000 deaths were attributed to cutaneous malignancies in the United States in 2005, most (7,770) from malignant melanoma.1 Moreover, both the incidence and mortality of skin cancers are increasing in the United States and throughout most of the world.2,3 Although this chapter focuses primarily on melanoma, a discussion of other cutaneous malignancies is included.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10–30.

    Article  PubMed  Google Scholar 

  2. Rigel DS. Malignant melanoma: incidence issues and their effect on diagnosis and treatment in the 1990s. Mayo Clin Proc 1997;72:367–371.

    Article  PubMed  CAS  Google Scholar 

  3. Weinstock MA. Issues in the epidemiology of melanoma. Hematol Oncol Clin N Am 1998;12:681–698.

    Article  CAS  Google Scholar 

  4. Wingo PA, Ries LAG, Rosenberg HM, Miller DS, Edwards BK. Cancer incidence and mortality. Cancer (Phila) 1998;82:1197–1207.

    Article  PubMed  CAS  Google Scholar 

  5. Albert VA, Koh HK, Geller AC, Miller DR, Prout MN, Lew RA. Years of potential life lost: another indicator of the impact of cutaneous malignant melanoma on society. J Am Acad Dermatol 1990;23:308–310.

    Article  PubMed  CAS  Google Scholar 

  6. Chaudru V, Chompret A, Bressac-de Paillerets B, Spatz A, Avril M-F, Demenais F. Influence of genes, nevi, and sun sensitivity on melanoma risk in a family sample unselected by family history and in melanoma-prone families. J Natl Cancer Inst 2004;96:785–795.

    PubMed  Google Scholar 

  7. Rouzaud F, Kadekaro AL, Abdel-Malek ZA, Hearing VJ. MC1R and the response of melanocytes to ultraviolet radiation. Mutat Res 2005;571:133–152.

    PubMed  CAS  Google Scholar 

  8. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and non-cutaneous melanoma: a summary of 84,836 cases from the past decade. Cancer (Phila) 1998;83:1664–1678.

    Article  PubMed  CAS  Google Scholar 

  9. Katz KA, Jonasch E, Hodi FS, et al. Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute. Melanoma Res 2005;15:77–82.

    Article  PubMed  Google Scholar 

  10. Cress RD, Holly EA. Incidence of cutaneous melanoma among non-Hispanic whites, Hispanics, Asians, and blacks: an analysis of California cancer registry data, 1988’93. Cancer Causes Control 1997;8:246–252.

    Article  PubMed  CAS  Google Scholar 

  11. Byrd KM, Wilson DC, Hoyler SS, Peck GL. Advanced presentation of melanoma in African Americans. J Am Acad Dermatol 2004;50:21–24.

    Article  PubMed  Google Scholar 

  12. Halder RM, Bridgeman-Shah S. Skin cancer in African Americans. Cancer (Phila) 1995;75:667–673.

    Article  PubMed  CAS  Google Scholar 

  13. Elwood JM, Jopson J. Melanoma and sun exposure: an overview of published studies. Int J Cancer 1997;73:198–203.

    Article  PubMed  CAS  Google Scholar 

  14. Langley RGB, Sober AJ. A clinical review of the evidence for the role of ultraviolet radiation in the etiology of cutaneous melanoma. Cancer Invest 1997;15:561–567.

    Article  PubMed  CAS  Google Scholar 

  15. Berwick M, Armstrong BK, Ben-Porat L, et al. Sun exposure and mortality from melanoma. J Natl Cancer Inst 2005;97:195–199.

    PubMed  Google Scholar 

  16. Tsao H, Sober A. Acquired precursor lesions and markers of increased risk for cutaneous melanoma. In: Balch C, Houghton A, Sober A, Soong S, eds. Cutaneous Melanoma, 4th ed. St. Louis: Quality Medical, 2003:121–134.

    Google Scholar 

  17. Tsao H, Bevona C, Goggins W, Quinn T. The transformation rate of moles (melanocytic nevi) into cutaneous melanoma: a population-based estimate. Arch Dermatol 2003;139:282–288.

    Article  PubMed  Google Scholar 

  18. Tucker MA, Halpern A, Holly EA, et al. Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA 1997;277:1439–1444.

    Article  PubMed  CAS  Google Scholar 

  19. Chin L. The genetics of malignant melanoma: lessons from mouse and man. Nat Rev Cancer 2003;3:559–570.

    Article  PubMed  CAS  Google Scholar 

  20. Chudnovsky Y, Khavari PA, Adams AE: Melanoma genetics and the development of rational therapeutics. J Clin Invest 2005;115:813–824.

    PubMed  CAS  Google Scholar 

  21. Greene MH, Clark WH Jr, Tucker MA, et al. Acquired precursors of cutaneous malignant melanoma: the familial dysplastic nevus syndrome. N Engl J Med 1985;312:91–97.

    PubMed  CAS  Google Scholar 

  22. Lynch HT, Fusaro RM, Pester J, Lynch JF. Familial atypical multiple mole melanoma (FAMMM) syndrome: genetic heterogeneity and malignant melanoma. Br J Cancer 1980;42:58–70.

    PubMed  CAS  Google Scholar 

  23. Bale SJ, Dracopoli NC, Tucker MA, et al. Mapping the gene for hereditary cutaneous malignant melanoma: dysplastic nevus to chromosome 1p. N Engl J Med 1989;320:1367–1372.

    PubMed  CAS  Google Scholar 

  24. Nancarrow DJ, Mann GJ, Holland EA, et al. Confirmation of chromosome 9p linkage in familial melanoma. Am J Hum Genet 1993;53:936–942.

    PubMed  CAS  Google Scholar 

  25. Marghoob AA, Schoenbach SP, Kopf AW, Orlow SJ, Nossa R, Bart RS. Large congenital melanocytic nevi and the risk for the development of malignant melanoma: a prospective study. Arch Dermatol 1996;132:170–175.

    Article  PubMed  CAS  Google Scholar 

  26. Nancarrow D, Platz A, Tucker MA for the Melanoma Genetics Consortium. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 2002;94:894–903.

    PubMed  Google Scholar 

  27. Meyskens FL, Farmer PJ, Anton-Culver H. Etiologic pathogenesis of melanoma: a unifying hypothesis for the missing attributable risk. Clin Cancer Res 2004;10:2581–2583.

    Article  PubMed  CAS  Google Scholar 

  28. Wellbrock C, Ogilvie L, Hedley D, Karasarides M, et al. V599EB-RAF is an oncogene in melanocytes. Cancer Res 2004;64:2338–2342.

    Article  PubMed  CAS  Google Scholar 

  29. Tsao H, Zhang X, Fowlkes K, Haluska FG. Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res 2000;60:1800–1804.

    PubMed  CAS  Google Scholar 

  30. Tsao H, Goel V, Wu H, Yang G, Haluska FG. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 2004;122:337–341.

    Article  PubMed  CAS  Google Scholar 

  31. Uribe P, Wistuba II, Gonzalez S. BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin. Am J Dermatopathol 2003;25:365–370.

    Article  PubMed  Google Scholar 

  32. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet 2003;33:19–20.

    Article  PubMed  CAS  Google Scholar 

  33. Dong J, Phelps RG, Qiao R, Yao S, Benard O, Ronai Z, Aaronson SA. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res 2003;63:3883–3885.

    PubMed  CAS  Google Scholar 

  34. Argenziano G, Soyer HP. Dermoscopy of pigmented skin lesions: a valuable tool for early diagnosis of melanoma. Lancet Oncol 2001;2:443–449.

    Article  PubMed  CAS  Google Scholar 

  35. Riker AI, Glass F, Perez I, Cruse CW, Messina J, Sondak VK. Cutaneous melanoma: methods of biopsy and definitive surgical excision. Dermatol Ther 2005;18:387–393.

    Article  PubMed  Google Scholar 

  36. Saiag P, Bernard M, Beauchet A, Bafounta ML, Bourgault-Villada I, Chagnon S. Ultrasonography using simple diagnostic criteria vs palpation for the detection of regional lymph node metastases of melanoma. Arch Dermatol 2005;141:183–189.

    Article  PubMed  Google Scholar 

  37. Starritt EC, Uren RF, Scolyer RA, Quinn MJ, Thompson JF. Ultrasound examination of sentinel nodes in the initial assessment of patients with primary cutaneous melanoma. Ann Surg Oncol 2005;12:18–23.

    Article  PubMed  Google Scholar 

  38. Basler GC, Fader DJ, Yahanda A, Sondak VK, Johnson TM. The utility of fine needle aspiration in the diagnosis of melanoma metastatic to lymph nodes. J Am Acad Dermatol 1997;36:403–408.

    Article  PubMed  CAS  Google Scholar 

  39. Clark WH, Elder DE, Guerry D, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989;81:1893–1904.

    Article  PubMed  Google Scholar 

  40. Balch CM, Soong S-J, Gershenwald JE, et al. Prognostic factor analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer Melanoma Staging System. J Clin Oncol 2001;19:3622–3234.

    PubMed  CAS  Google Scholar 

  41. Weinstock MA, Morris BT, Lederman JS, Bleicher P, Fitzpatrick TB, Sober AJ. Effect of BANS location on the prognosis of clinical stage I melanoma: new data and meta-analysis. Br J Dermatol 1988;119:559–565.

    Article  PubMed  CAS  Google Scholar 

  42. Fidler IJ, Ellis LM. Neoplastic angiogenesis. Not all blood vessels are created equal. N Engl J Med 2004;351:215–216.

    Article  PubMed  CAS  Google Scholar 

  43. Sondak VK, Taylor JM, Sabel MS, et al. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol 2004;11:247–258.

    Article  PubMed  Google Scholar 

  44. Barnhill RL, Katzen J, Spatz A, Fine J, Berwick M. The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma. J Cutan Pathol 2005;32:268–273.

    Article  PubMed  Google Scholar 

  45. Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer (Phila) 1996;77:1303–1310.

    Article  PubMed  CAS  Google Scholar 

  46. Tuthill RJ, Unger JM, Liu PY, Flaherty LE, Sondak VK, for the Southwest Oncology Group. Risk assessment in localized primary cutaneous melanoma: a Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model. Am J Clin Pathol 2002;118:504–511.

    Article  PubMed  Google Scholar 

  47. Hawkins WG, Busam KJ, Ben-Porat L, et al. Desmoplastic melanoma: a pathologically and clinically distinct form of cutaneous melanoma. Ann Surg Oncol 2005;12:207–213.

    Article  PubMed  Google Scholar 

  48. Balch CM, Soong S, Shaw HM, Urist MM, McCarthy WH. An analysis of prognostic factors in 8500 patients with cutaneous melanoma. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong S, ed. Cutaneous Melanoma, 2nd ed. Philadelphia: Lippincott, 1992:165–187.

    Google Scholar 

  49. Ferrari A, Bono A, Baldi M, et al. Does melanoma behave differently in younger children than in adults? A retrospective study of 33 cases of childhood melanoma from a single institution. Pediatrics 2005;115:649–654.

    Article  PubMed  Google Scholar 

  50. Chao MM, Schwartz JL, Wechsler DS, Thornburg CD, Griffith KA, Williams JA. High-risk surgically resected pediatric melanoma and adjuvant interferon therapy. Pediatr Blood Cancer 2004;43:1–8.

    Article  Google Scholar 

  51. Veronesi U, Cascinelli N, Adamus J, et al. Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3cm. N Engl J Med 1988;318:1159–1162.

    Article  PubMed  CAS  Google Scholar 

  52. Veronesi U, Cascinelli N. Narrow excision (1-cm margin): a safe procedure for thin cutaneous melanoma. Arch Surg 1991;126:438–441.

    PubMed  CAS  Google Scholar 

  53. Karakousis CP, Balch CM, Urist MM, Ross MM, Smith TJ, Bartolucci AA. Local recurrence in malignant melanoma: long-term results of the multiinstitutional randomized surgical trial. Ann Surg Oncol 1996;3:446–452.

    Article  PubMed  CAS  Google Scholar 

  54. Balch CM, Urist MM, Karakousis CP, et al. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1-4mm): results of a multi-institutional randomized surgical trial. Ann Surg 1993;218:262–269.

    Article  PubMed  CAS  Google Scholar 

  55. Thomas JM, Newton-Bishop J, Ahern R, et al. Excision margins in high-risk malignant melanoma. N Engl J Med 2004;350:757–766.

    Article  PubMed  CAS  Google Scholar 

  56. Johnson TM, Sondak VK. Melanoma margins: the importance and need for more evidence-based trials. Arch Dermatol 2004;140:1148–1150.

    Article  PubMed  Google Scholar 

  57. Heaton KM, Sussman JJ, Gershenwald JE, et al. Surgical margins and prognostic factors in patients with thick (0.4 mm) primary melanoma. Ann Surg Oncol 1998;5:322–328.

    Article  PubMed  CAS  Google Scholar 

  58. Kesmodel SB, Karakousis GC, Botbyl JD, et al. Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol 2005;12:1–10.

    Article  Google Scholar 

  59. Gimotty PA, Van Belle P, Elder DE, et al. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumor-igenicity in thin invasive cutaneous melanoma. J Clin Oncol 2005;23:8048–8056.

    Article  PubMed  Google Scholar 

  60. Puleo CA, Messina JL, Riker AI, et al. Sentinel node biopsy for thin melanomas: which patients should be considered? Cancer Control 2005,12:230–235.

    PubMed  Google Scholar 

  61. Balch CM. The role of elective lymph node dissection in melanoma: rationale, results, and controversies. J Clin Oncol 1988;6:163–172.

    PubMed  CAS  Google Scholar 

  62. Balch CM, Soong SJ, Bartolucci AA, et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 1996;224:255–263.

    Article  PubMed  CAS  Google Scholar 

  63. Sim FH, Taylor WF, Ivins JC, et al. A prospective randomized study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma: preliminary results. Cancer (Phila) 1978;41:948–956.

    Article  PubMed  CAS  Google Scholar 

  64. Veronesi U, Adamus J, Bandiera DC, et al. Delayed regional node dissection in stage I melanoma of the skin of the lower extremities. Cancer (Phila) 1982;49:2420–2430.

    Article  PubMed  CAS  Google Scholar 

  65. Cascinelli N, Morabito A, Santinami M, MacKie RM, Belli F. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet 1998;351:793–796.

    Article  PubMed  CAS  Google Scholar 

  66. Morton DL, Wen D-R, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392–399.

    PubMed  CAS  Google Scholar 

  67. Reintgen DS, Brobeil A. Lymphatic mapping and selective lymphadenectomy as an alternative to elective lymph node dissection in patients with malignant melanoma. Hematol Oncol Clin N Am 1998;12:807–821.

    Article  CAS  Google Scholar 

  68. Bostick P, Essner R, Glass E, et al. Comparison of blue dye and probe-assisted intraoperative lymphatic mapping in melanoma to identify sentinel nodes in 100 lymphatic basins. Arch Surg 1999;134:43–49.

    Article  PubMed  CAS  Google Scholar 

  69. Evans HL, Krag DN, Teates CD, et al. Lymphoscintigraphy and sentinel node biospy accurately stage melanoma in patients presenting after wide local excision. Ann Surg Oncol 2003;10:416–425.

    Article  PubMed  Google Scholar 

  70. Gershenwald JE, Colome MI, Lee JE, et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 1998;6:2253–2260.

    Google Scholar 

  71. Morton DL, Thompson JF, Cochran AJ, et al. Interim results of the Multicenter Selective Lymphadenectomy Trial (MSLT-1) in clinical stage I melanoma. J Clin Oncol 2005;23:abstract 7500.

    Google Scholar 

  72. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation for melanoma. N Engl J Med 2006;355:1307–1317.

    Article  PubMed  CAS  Google Scholar 

  73. Wang X, Heller R, VanVoorhis N, et al. Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma. Ann Surg 1994;220:768–774.

    Article  PubMed  CAS  Google Scholar 

  74. Shivers SC, Wang X, Li W, et al. Molecular staging of malignant melanoma: correlation with clinical outcome. JAMA 1998;280:1410–1415.

    Article  PubMed  CAS  Google Scholar 

  75. Scoggins CR, Ross MI, Reintgen DS, et al. Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma. J Clin Oncol 2006;24:2849–2857.

    Article  PubMed  CAS  Google Scholar 

  76. Poo-Hwu WJ, Ariyan S, Lamb L, et al. Follow-up recommendations for patients with American Joint Commission on Cancer stages I-III malignant melanoma. Cancer (Phila) 1999;86:2252–2258.

    Article  PubMed  CAS  Google Scholar 

  77. Baergen RN, Johnson D, Moore T, Benirschke K. Maternal melanoma metastatic to the placenta. Arch Pathol Lab Med 1997;121:508–511.

    PubMed  CAS  Google Scholar 

  78. Mackie RM. Pregnancy and exogenous hormones in patients with cutaneous malignant melanoma. Curr Opin Oncol 1999;11:129–131.

    Article  PubMed  CAS  Google Scholar 

  79. Collaborative Ocular Melanoma Study Group. Mortality in patients with small choroidal melanoma. COMS report no. 4. Arch Ophthalmol 1997;115(7):886–893.

    Google Scholar 

  80. Jampol LM, Moy CS, Murray TG, et al. The COMS randomized trial of iodine 125 bryachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19. Ophthalmology 2002;109:2197–2206.

    Article  PubMed  Google Scholar 

  81. Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study (COMS) randomized trial of preenucleation radiation of large choroidal melanoma II: initial mortality findings. COMS report no. 10. Am J Ophthalmol 1998;125:779–796.

    Article  Google Scholar 

  82. Cooper JS. The evolution of the role of radiation therapy in the management of mucocutaneous malignant melanoma. Hematol Oncol Clin N Am 1998;12:849–862.

    Article  CAS  Google Scholar 

  83. Sondak VK, Wolfe JA. Adjuvant therapy for melanoma. Curr Opin Oncol 1997;9:189–204.

    Article  PubMed  CAS  Google Scholar 

  84. Veronesi U, Adamus J, Aubert C, et al. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 1982;307:913–916.

    PubMed  CAS  Google Scholar 

  85. Quirt IC, Shelley WE, Pater JL, et al. Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1991;9:729–735.

    PubMed  CAS  Google Scholar 

  86. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol 1996;14:7–17.

    PubMed  CAS  Google Scholar 

  87. Kirkwood JM, Ibrahim JG, Sondak VK, et al. High-and low-dose interferon alfa-2b in high-risk melanoma: first analysis of inter-group trial E1690/S9111/C9190. J Clin Oncol 2000;18:2444–2458.

    PubMed  CAS  Google Scholar 

  88. Creagan ET, Dalton RJ, Ahmann DL, et al. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 1995;13:2776–2783.

    PubMed  CAS  Google Scholar 

  89. Cascinelli N, Bufalino R, Morabito A, MacKie RM. Results of adjuvant interferon study in WHO melanoma programme. Lancet 1994;343:913–914.

    Article  PubMed  CAS  Google Scholar 

  90. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao M. A pooled analysis of Eastern Cooperative Group and Inter-group trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004;10:1670–1677.

    Article  PubMed  CAS  Google Scholar 

  91. Schuchter LM. Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose? J Clin Oncol 2004;22:7–10.

    Article  PubMed  CAS  Google Scholar 

  92. Morton DL, Mozzillo N, Thompson JF, et al. An international randomized double blind, phase 3 study of the specific active immunotherapy agent, onamelatucel-L (Canvaxin), compared to placebo as a post-surgical adjuvant in AJCC stage IV melanoma. Ann Surg Oncol 2006;13:5 (abstract).

    Article  Google Scholar 

  93. Spitler LE, Grossbard ML, Ernstoff MS, et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol 2000;18:1614–1621.

    PubMed  CAS  Google Scholar 

  94. Speiser DE, Lienard D, Rufer N, et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IF A, and CpG oligodeoxynucleotide 7909. J Clin Invest 2005;115:739–746.

    PubMed  CAS  Google Scholar 

  95. Ang KK, Peters LJ, Weber RS, et al. Postoperative radiotherapy for cutaneous melanoma of the head and neck region. Int J Radiat Oncol Biol Phys 1994;30:795–798.

    PubMed  CAS  Google Scholar 

  96. Strom EA, Ross MI. Adjuvant radiation therapy after axillary lymphadenectomy for metastatic melanoma: toxicity and local control. Ann Surg Oncol 1995;2:445–449.

    Article  PubMed  CAS  Google Scholar 

  97. O’Brien CJ, Petersen-Schaefer K, Stevens GN, et al. Adjuvant radiotherapy following neck dissection and parotidectomy for metastatic malignant melanoma. Head Neck 1997;19:589–594.

    Article  PubMed  Google Scholar 

  98. Creagan ET, Cupps RE, Ivins JC, et al. Adjuvant radiation therapy for regional nodal metastases from malignant melanoma: a randomized, prospective study. Cancer (Phila) 1978;42:2206–2210.

    Article  PubMed  CAS  Google Scholar 

  99. Eggermont AM, Brunstein F, Grunhagen D, ten Hagen TL. Regional treatment of metastasis: role of regional perfusion. State of the art isolated limb perfusion for limb salvage. Ann Oncol 2004;15(suppl 4):iv-107–iv-112.

    Google Scholar 

  100. Taber SW, Polk HC Jr. Mortality, major amputation rates, and leukopenia after isolated limb perfusion with phenylalanine mustard for the treatment of melanoma. J Surg Oncol 1997;4:440–445.

    Article  CAS  Google Scholar 

  101. Lienard D, Ewalenko P, Delmotte J-J, Renard N, Lejeune FJ. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992;10:52–60.

    PubMed  CAS  Google Scholar 

  102. Fraker DL, Alexander HR, Andrich M, Rosenberg SA. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. J Clin Oncol 1996;14:479–489.

    PubMed  CAS  Google Scholar 

  103. Thompson JF, Kam PC. Isolated limb infusion for melanoma: a simple but effective alternative to isolated limb perfusion. J Surg Oncol 2004;88(1):1–3.

    Article  PubMed  Google Scholar 

  104. Schraffordt Koops H, Vaglini M, Suciu S, et al. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase HI trial. J Clin Oncol 1998;16:2906–2912.

    Google Scholar 

  105. Margolin K, Atkins MB, Thompson JA, et al. Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. J Cancer Res Clin Oncol 2002;128:214–218.

    Article  PubMed  CAS  Google Scholar 

  106. Atkins MB, Sosman J, Agarwala S, et al. A Cytokine Working Group phase II study of temozolomide (TMZ), thalidomide (THAL) and whole brain radiation therapy (WBRT) for patients with brain metastases from melanoma. Proc Am Soc Clin Oncol 2005;23:723S.

    Google Scholar 

  107. Ang KK, Geara FB, Byers RM, Peters LJ. Radiotherapy of melanoma. In: Balch CM, Houghton AN, Sober AJ, Soong S, eds. Cutaneous Melanoma, 3rd ed. St. Louis: Quality Medical, 1998:389–403.

    Google Scholar 

  108. Wu H, Goel V, Haluska FG. PTEN signaling pathways in melanoma. Oncogene 2003;22:3113–3122.

    Article  PubMed  CAS  Google Scholar 

  109. Flaherty KT. New molecular targets in melanoma. Curr Opin Oncol 2004;16:150–154.

    Article  PubMed  CAS  Google Scholar 

  110. Legha SS. The role of interferon alfa in the treatment of metastatic melanoma. Semin Oncol 1997;24(1 suppl 4):S24–S31.

    PubMed  CAS  Google Scholar 

  111. Atkins MB. Immunotherapy and experimental approaches for metastatic melanoma. Hematol Oncol Clin N Am 1998;12:877–902.

    Article  CAS  Google Scholar 

  112. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. f Clin Oncol 1999;17:2105–2116.

    CAS  Google Scholar 

  113. Margolin K. Biochemotherapy for melanoma: rational therapeutics in the search for weapons of melanoma destruction. Cancer (Phila) 2004;101:435–438.

    Article  PubMed  CAS  Google Scholar 

  114. Sondak VK, Sosman JA. Results of clinical trials with an allogeneic melanoma tumor cell lysate vaccine: Melacine®. Semin Cancer Biol 2003;13:409–415.

    Article  PubMed  CAS  Google Scholar 

  115. Mitchell MS, Harel W, Kempf RA, et al. Active-specific immunotherapy for melanoma. J Clin Oncol 1990;8:856–869.

    PubMed  CAS  Google Scholar 

  116. Demierre M-F, Swetter SM, Sondak VK. Vaccine therapy of melanoma: an update. Curr Cancer Ther Rev 2005;1:115–125.

    Article  CAS  Google Scholar 

  117. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19:2370–2380.

    PubMed  CAS  Google Scholar 

  118. Panelli MC, Wang E, Monsurro W, et al. Overview of melanoma vaccines and promising approaches. Curr Oncol Rep 2004;6:414–420.

    Article  PubMed  Google Scholar 

  119. Perales MA, Wolchok JD. Melanoma vaccines. Cancer Invest 2002;20:1012–1026.

    Article  PubMed  Google Scholar 

  120. Antonia S, Mule JJ, Weber JS. Current developments of immunotherapy in the clinic. Curr Opin Immunol 2004;16:130–136.

    Article  PubMed  CAS  Google Scholar 

  121. Preston DS, Stern RS. Nonmelanoma cancers of the skin. N Engl J Med 1992;327:1649–1662.

    PubMed  CAS  Google Scholar 

  122. Halpern AC, Altman JF. Genetic predisposition to skin cancer. Curr Opin Oncol 1999;11:132–138.

    Article  PubMed  CAS  Google Scholar 

  123. Brooks AD, Heslin MJ, Leung DH, Lewis JJ, Brennan MF. Superficial extremity soft tissue sarcoma: an analysis of prognostic factors. Ann Surg Oncol 1998;5:41–47.

    Article  PubMed  CAS  Google Scholar 

  124. Swanson NA. Mohs surgery: technique, indications, applications, and the future. Arch Dermatol 1983;119:761–773.

    Article  PubMed  CAS  Google Scholar 

  125. Ratner D, Thomas CO, Johnson TM, et al. Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans: results of a multi-institutional series with an analysis of the extent of microscopic spread. J Am Acad Dermatol 1997;37:600–613.

    Article  PubMed  CAS  Google Scholar 

  126. Messina JL, Reintgen DS, Cruse CW, et al. Selective lymphadenectomy in patients with Merkel cell (cutaneous neuroendocrine) carcinoma. Ann Surg Oncol 1997;4:389–395.

    Article  PubMed  CAS  Google Scholar 

  127. Lippman SM, Parkinson DR, Itri LM, et al. 13-cis-Retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 1992;84:235–241.

    Article  PubMed  CAS  Google Scholar 

  128. Meyskens FL Jr, Kopecky K, Taylor CW, et al. Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma. J Natl Cancer Inst 1995;87:1710–1713.

    Article  PubMed  Google Scholar 

  129. Sondak VK, Kopecky KJ, Smith JW II, et al. Is interferon-a detrimental? Results of a Southwest Oncology Group randomized trial of adjuvant human interferon-a versus observation in malignant melanoma. In: Salmon SE, ed. Adjuvant Therapy of Cancer, vol VIII. Philadelphia: Lippincott-Raven, 1997:259–272.

    Google Scholar 

  130. Rusciani L, Petraglia S, Alotto M, et al. Postsurgical adjuvant therapy of melanoma: evaluation of a 3-year randomized trial with recombinant interferon-a after 3 and 5 years of follow-up. Cancer (Phila) 1997;79:2354–2360.

    Article  PubMed  CAS  Google Scholar 

  131. Pehamberger H, Soyer HP, Steiner A, et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. J Clin Oncol 1998;16:1425–1429.

    PubMed  CAS  Google Scholar 

  132. Grob JJ, Dreno B, de la Salmonière P, et al. Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. Lancet 1998;351:1905–1910.

    Article  PubMed  CAS  Google Scholar 

  133. Berd D, Sato T, Maguire HC Jr, Kairys J, Mastrangelo MJ. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol 2004;22:403–415.

    Article  PubMed  CAS  Google Scholar 

  134. Hsueh EC, Morton DL. Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine. Semin Cancer Biol 2003;13:401–417.

    Article  PubMed  CAS  Google Scholar 

  135. Livingston PO, Wong GYC, Adluri S, et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994;12:1036–1044.

    PubMed  CAS  Google Scholar 

  136. Rosenberg SJ, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909–915.

    Article  PubMed  CAS  Google Scholar 

  137. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma J Clin Oncol 23:2346–2357.

    Google Scholar 

  138. Lonchay C, van der Bruggen P, Connerotte T, et al. Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc Natl Acad Sci USA 2004;101(suppl 2):14631–14638.

    Article  PubMed  CAS  Google Scholar 

  139. Slingluff CL Jr, Petroni GR, Yamshchikov GV, et al. Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. J Clin Oncol 2004;22:4474–4485.

    Article  PubMed  CAS  Google Scholar 

  140. Klinman D. Immunotherapeutic uses of CpG oligodeoxynucleo-tides. Nat Rev Immunol 2004;4:249–258.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cutaneous Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

    Vernon K. Sondak MD (Chief and Professor)

  2. Departments of Surgery and Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

    Vernon K. Sondak MD (Chief and Professor)

  3. Department of Surgical Oncology, H. Lee Moffltt Cancer Center and Research Institute, Tampa, FL, USA

    Eric H. Jensen MD (Fellow)

  4. Division of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA, USA

    Kim A. Margolin MD (Associate Director for Clinical Research, Professor and Staff Physician)

  5. Division of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA

    Kim A. Margolin MD (Associate Director for Clinical Research, Professor and Staff Physician)

  6. Medical Oncology, City of Hope National Medical Center, Duarte, CA, USA

    Kim A. Margolin MD (Associate Director for Clinical Research, Professor and Staff Physician)

Authors
  1. Vernon K. Sondak MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eric H. Jensen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kim A. Margolin MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Surgery, Stanford University Medical Center, Stanford, CA, USA

    Jeffrey A. Norton MD, FACS (Robert L. and Mary Ellenburg Professor, Chief) (Robert L. and Mary Ellenburg Professor, Chief)

  2. Divisions of Surgical Oncology and General Surgery, Department of Surgery, Stanford University Medical Center, Stanford, CA, USA

    Jeffrey A. Norton MD, FACS (Robert L. and Mary Ellenburg Professor, Chief) (Robert L. and Mary Ellenburg Professor, Chief)

  3. Departments of Surgery and Public Health, New York-Presbyterian Hospital/Weill Cornell Medical College, New York, NY, USA

    Philip S. Barie MD, MBA, FCCM, FACS (Professor, Chief) (Professor, Chief)

  4. Division of Critical Care and Trauma, NewYork-Presbyterian Hospital/Weill Cornell Medical College, New York, NY, USA

    Philip S. Barie MD, MBA, FCCM, FACS (Professor, Chief) (Professor, Chief)

  5. Departments of Surgery and Immunology, Duke University Medical Center, Durham, NC, USA

    R. Randal Bollinger MD, PhD, FACS (Professor) (Professor)

  6. Division of Surgical Oncology, Department of Surgery, University of Michigan, Comprehensive Cancer Center, Ann Arbor, MI, USA

    Alfred E. Chang MD, FACS (Chief, Hugh Cabot Professor of Surgery) (Chief, Hugh Cabot Professor of Surgery)

  7. Department of Surgery, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ, USA

    Stephen F. Lowry MD, MBA, FACS (Professor and Chairman) (Professor and Chairman)

  8. Robert Wood Johnson Medical School, New Brunswick, NJ, USA

    Stephen F. Lowry MD, MBA, FACS (Professor and Chairman) (Professor and Chairman)

  9. Department of Surgery, The University of Utah, Salt Lake City, UT, USA

    Sean J. Mulvihill MD, FACS (Professor and Chair, Senior Director of Clinical Affairs) (Professor and Chair, Senior Director of Clinical Affairs)

  10. Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT, USA

    Sean J. Mulvihill MD, FACS (Professor and Chair, Senior Director of Clinical Affairs) (Professor and Chair, Senior Director of Clinical Affairs)

  11. Departments of Cardiothoracic Surgery and Surgery, New York University Medical Center, New York, NY, USA

    Harvey I. Pass MD, FACS (Professor) (Professor)

  12. Radiology, and Cell Biology and Physiology, Washington University School of Medicine, St. Louis, MO, USA

    Robert W. Thompson MD, FACS (Professor of Surgery (Section of Vascular Surgery), Vice-Chairman for Research) (Professor of Surgery (Section of Vascular Surgery), Vice-Chairman for Research)

  13. Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA

    Robert W. Thompson MD, FACS (Professor of Surgery (Section of Vascular Surgery), Vice-Chairman for Research) (Professor of Surgery (Section of Vascular Surgery), Vice-Chairman for Research)

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Sondak, V.K., Jensen, E.H., Margolin, K.A. (2008). Melanoma and Other Cutaneous Malignancies. In: Norton, J.A., et al. Surgery. Springer, New York, NY. https://doi.org/10.1007/978-0-387-68113-9_98

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-68113-9_98

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-30800-5

  • Online ISBN: 978-0-387-68113-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation